Subscribe
shutterstock_1635596416_sundry_photography
Sundry Photography / Shutterstock.com
14 December 2020Big PharmaMuireann Bolger

Amgen faces struggle to revive cholesterol patents, says Fed Circ judge

Amgen is unlikely to succeed in its bid to revive its patents for the cholesterol drug Repatha, a judge at the US Court of Appeals for the Federal Circuit has told the pharmaceutical company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Amgen announces $13.4bn acquisition of Celgene psoriasis treatment
27 August 2019   Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.
Americas
Amgen and Sandoz face off again over biosimilars
3 March 2016   Amgen and Sandoz are set to go head to head in another patent case, this time centring on Amgen’s arthritis treatment drug Enbrel.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Amgen announces $13.4bn acquisition of Celgene psoriasis treatment
27 August 2019   Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.
Americas
Amgen and Sandoz face off again over biosimilars
3 March 2016   Amgen and Sandoz are set to go head to head in another patent case, this time centring on Amgen’s arthritis treatment drug Enbrel.

More on this story

Big Pharma
Amgen announces $13.4bn acquisition of Celgene psoriasis treatment
27 August 2019   Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.
Americas
Amgen and Sandoz face off again over biosimilars
3 March 2016   Amgen and Sandoz are set to go head to head in another patent case, this time centring on Amgen’s arthritis treatment drug Enbrel.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB